# A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

> **NCT07422480** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 300 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Anemia

## Interventions

- **DRUG:** Elritercept
- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT07422480
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-04-30
- **Final completion:** 2033-10-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422480, "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT07422480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*